Zimbabwe has rejected a major American health deal valued at 367 million US dollars (£272m) over five years due to the United States' insistence on sensitive data.
The decision came to light after a official document from December was disclosed, indicating that Head of State Emmerson Mnangagwa felt the deal was "skewed".
A government spokesman has since stated that the United States was demanding access to biological samples for scientific study and profit but was not willing to share the resulting advantages from future treatments.
"We will now turn to the difficult and regrettable process of ending our health assistance in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy indicated the US had provided over $1.9bn in health funding to Zimbabwe over the last twenty years.
A physicians' group in Zimbabwe has urged continued talks to reach a agreement suitable to all parties so the country's vital HIV programme can proceed.
Broader Implications
Zimbabwe's decision follows a similar case in Kenya, where a court halted a similar health funding agreement following concerns were raised about the security of citizens' health data.
After resuming the presidency recently, US President Donald Trump has drastically cut overseas assistance and closed the US Agency for International Development (USAID).
USAID had managed aid for the US government, but Trump stated its expenditure was "wasteful" and his administration was pursuing government-to-government agreements to boost openness and responsibility.
According to reports, Sixteen nations in Africa have to date agreed to similar agreements, representing over $18.3bn in committed funds.
Specifics of the Declined Agreement
The money for Zimbabwe was intended to funded "tackling HIV/Aids, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"It is our view this partnership could have provided immense benefits for the people of Zimbabwe, especially the 1.2 million presently receiving HIV treatment via US-supported programmes," the Ambassador said.
However, official spokesman Nick Mangwana maintained the arrangement was "asymmetrical".
"Zimbabwe was being asked to provide its genetic material and health information indefinitely, without any equivalent promise of access to any medical innovations – such as vaccines, diagnostics, or treatments – that could be developed from that shared data," his statement read.
"In essence, our nation would provide the basic resources for scientific discovery without any certainty that the resulting innovations would be available to our population if a future pandemic emerge."
Sovereignty and Global Health
He also noted that the American exit from the global health body and its pursuit of one-on-one health agreements were upending structures previously set up through the global health agency.
Mangwana cited its Pathogen Access and Benefit Sharing framework designed to deal with potential global health emergencies.
"This system is designed to ensure that when a country provides its information, the benefits – including vaccines and treatments – are shared equitably, not monopolised exclusively by those with the capability to develop them."
Zimbabwe's reservations over the US deal "are not meant as opposition to America," Mangwana stressed.
"We welcome continued dialogue with our US partners on how subsequent collaboration might be structured in a manner that respects the sovereignty and interests of each country."
Health Experts Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) stated it acknowledged the official position, but recommended that negotiations need to persist considering a large portion of the nation's Aids initiatives were funded by external financing.
"Where specific concerns exist, including those involving data governance or agreement terms, these can often be resolved through technical clarification and negotiated safeguards," the group commented.
The situation highlights the complex challenges between receiving crucial international aid and protecting a country's data in an increasingly interconnected world.